IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the … Continue reading →

IGC Pharma (NYSE American: IGC) today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of its ongoing phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for … Continue reading →

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced that it is presenting six in-person posters highlighting data from its phase 1 clinical trials investigating the company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”). … Continue reading →

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug … Continue reading →

IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an … Continue reading →

IGC Pharma (NYSE American: IGC) today announced recognition of its advisor, Professor T. Govindaraju, the inventor of the investigational Alzheimer’s drug candidate, TGR-63. According to the announcement, Govindaraju received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding … Continue reading →